Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates

ABSTRACT Understanding the physical characteristics of the local microenvironment in which Mycobacterium tuberculosis resides is an important goal that may allow the targeting of metabolic processes to shorten drug regimens. Pimonidazole hydrochloride (Hypoxyprobe) is an imaging agent that is bioreductively activated only under hypoxic conditions in mammalian tissue. We employed this probe to evaluate the oxygen tension in tuberculous granulomas in four animal models of disease: mouse, guinea pig, rabbit, and nonhuman primate. Following infusion of pimonidazole into animals with established infections, lung tissues from the guinea pig, rabbit, and nonhuman primate showed discrete areas of pimonidazole adduct formation surrounding necrotic and caseous regions of pulmonary granulomas by immunohistochemical staining. This labeling could be substantially reduced by housing the animal under an atmosphere of 95% O2. Direct measurement of tissue oxygen partial pressure by surgical insertion of a fiber optic oxygen probe into granulomas in the lungs of living infected rabbits demonstrated that even small (3-mm) pulmonary lesions were severely hypoxic (1.6 ± 0.7 mm Hg). Finally, metronidazole, which has potent bactericidal activity in vitro only under low-oxygen culture conditions, was highly effective at reducing total-lung bacterial burdens in infected rabbits. Thus, three independent lines of evidence support the hypothesis that hypoxic microenvironments are an important feature of some lesions in these animal models of tuberculosis.

[1]  T. Laskay,et al.  Interferon‐gamma‐dependent mechanisms of mycobacteria‐induced pulmonary immunopathology: the role of angiostasis and CXCR3‐targeted chemokines for granuloma necrosis , 2007, The Journal of pathology.

[2]  S. Ehlers,et al.  Location of Persisting Mycobacteria in a Guinea Pig Model of Tuberculosis Revealed by R207910 , 2007, Antimicrobial Agents and Chemotherapy.

[3]  S. Ehlers,et al.  Oxygen status of lung granulomas in Mycobacterium tuberculosis‐infected mice , 2006, The Journal of pathology.

[4]  J. Flynn,et al.  Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension , 2006, Cellular microbiology.

[5]  So H. Kim,et al.  Interspecies pharmacokinetic scaling of DA‐8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics , 2005, Biopharmaceutics & drug disposition.

[6]  S. Kaufmann,et al.  Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma. , 2005, The Journal of infectious diseases.

[7]  R. Chaisson,et al.  Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[8]  M. Reed,et al.  A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response , 2004, Nature.

[9]  I. Orme,et al.  Rapid Accumulation of Eosinophils in Lung Lesions in Guinea Pigs Infected with Mycobacterium tuberculosis , 2004, Infection and Immunity.

[10]  G. Kaplan,et al.  Mycobacterium tuberculosis Growth at theCavity Surface: a Microenvironment with FailedImmunity , 2003, Infection and Immunity.

[11]  James E Gomez,et al.  Life on the inside for Mycobacterium tuberculosis , 2003, Nature Medicine.

[12]  JoAnne L. Flynn,et al.  Experimental Mycobacterium tuberculosis Infection of Cynomolgus Macaques Closely Resembles the Various Manifestations of Human M. tuberculosis Infection , 2003, Infection and Immunity.

[13]  Harvey Rubin,et al.  The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Kantharaj,et al.  Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[15]  M. Varia,et al.  Semiquantitative immunohistochemical analysis for hypoxia in human tumors. , 2001, International journal of radiation oncology, biology, physics.

[16]  N. Idkaidek,et al.  Enhancement of oral absorption of metronidazole suspension in humans. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  M. Varia,et al.  A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  S. Furney,et al.  Metronidazole Therapy in Mice Infected with Tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.

[19]  C. N. Paramasivan,et al.  Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. , 1998, The Indian journal of medical research.

[20]  G. Arteel,et al.  Cyclosporin A increases hypoxia and free radical production in rat kidneys: prevention by dietary glycine. , 1998, American journal of physiology. Renal physiology.

[21]  D. Mitchison,et al.  Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[22]  M C Weissler,et al.  Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. , 1998, Cancer research.

[23]  J. Raleigh,et al.  Identification of nonproliferating but viable hypoxic tumor cells in vivo. , 1998, Cancer research.

[24]  N. Lounis,et al.  Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. , 1998, American journal of respiratory and critical care medicine.

[25]  G. Arteel,et al.  Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. , 1998, European journal of biochemistry.

[26]  R. Long,et al.  Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. , 1998, Chest.

[27]  F. Verhaegen,et al.  High resolution chest CT in tuberculosis: evolutive patterns and signs of activity. , 1997, Journal of computer assisted tomography.

[28]  L. Wayne,et al.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.

[29]  G. Arteel,et al.  Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. , 1995, British Journal of Cancer.

[30]  L. Wayne,et al.  Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis , 1994, Antimicrobial Agents and Chemotherapy.

[31]  J. Im,et al.  Pulmonary tuberculosis: CT findings--early active disease and sequential change with antituberculous therapy. , 1993, Radiology.

[32]  S. Kamat,et al.  Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. , 1989, The Journal of the Association of Physicians of India.

[33]  Gilla Kaplan,et al.  The cutaneous infiltrates of leprosy. A transmission electron microscopy study , 1983, The Journal of experimental medicine.

[34]  D. Smith,et al.  Host-parasite relationships in experimental airborne tuberculosis. 3. Relevance of microbial enumeration to acquired resistance in guinea pigs. , 1970, The American review of respiratory disease.

[35]  G. Gensini,et al.  Studies on the gaseous content of tuberculous cavities. , 1959, The American review of respiratory disease.

[36]  J. Sever,et al.  Enumeration of viable tubercle bacilli from the organs of nonimmunized and immunized mice. , 1957, American review of tuberculosis.

[37]  J. Sever,et al.  The relation of oxygen tension to virulence of tubercle bacilli and to acquired resistance in tuberculosis. , 1957, The Journal of infectious diseases.

[38]  H. E. Kennedy,et al.  THE TREATED PULMONARY LESION AND ITS TUBERCLE BACILLUS III. DRUG SUSCEPTIBILITY STUDIES , 1957, The American journal of the medical sciences.

[39]  J. Sever,et al.  The enumeration of nonpathogenic viable tubercle bacilli from the organs of mice. , 1957, American review of tuberculosis.

[40]  H. M. Vandiviere,et al.  THE TREATED PULMONARY LESION AND ITS TUBERCLE BACILLUS.*: II. THE DEATH AND RESURRECTION , 1956, The American journal of the medical sciences.

[41]  H. M. Vandiviere,et al.  THE TREATED PULMONARY LESION AND ITS TUBERCLE BACILLUS I. PATHOLOGY AND PATHOGENESIS , 1956, The American journal of the medical sciences.

[42]  Loring We,et al.  The treated pulmonary lesion and its tubercle bacillus. I. Pathology and pathogenesis. , 1956 .

[43]  J. Dannenberg.  Pathogenesis of Human Pulmonary Tuberculosis: Insights from the Rabbit Model , 2006 .

[44]  G. Schoolnik,et al.  Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. , 2004, Tuberculosis.

[45]  James E Gomez,et al.  M. tuberculosis persistence, latency, and drug tolerance. , 2004, Tuberculosis.

[46]  S. Dische,et al.  The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans , 2004, European Journal of Clinical Pharmacology.

[47]  C. Sohaskey,et al.  Nonreplicating persistence of mycobacterium tuberculosis. , 2001, Annual review of microbiology.

[48]  R. Namdar,et al.  Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. , 1999, Chest.